Dare Bioscience Announces Interim Safety And Efficacy Results From Phase 3 Clinical Trial Of Ovaprene
Benzinga Newsdesk 5 months ago
BiotechNewsGeneral
Second Positive DSMB Review Supports Continued Study ProgressInterim Phase 3 Results Support Ovaprene's Differentiation as a First-in-Category, Hormone-Free, Intravaginal Monthly Contraceptive
Second Positive DSMB Review Supports Continued Study Progress
Interim Phase 3 Results Support Ovaprene's Differentiation as a First-in-Category, Hormone-Free, Intravaginal Monthly Contraceptive